Ackman Sells Valeant; Elliott has new, potentialy explosive claims in its fight with ArconicGuest Post
So ends Bill Ackman's valiant effort to prove that platform value is just like any other kind of value.
Pershing Square Capital Management’s three-year partnership with Valeant Pharmaceuticals International, which comprised a lucrative but legally controversial and ultimately unsuccessful takeover bid for botox-maker Allergan, a lengthy commendation of CEO Mike Pearson’s strategic genius at the Sohn Conference in 2015, and $4 billion in losses – roughly equivalent to gains on Canadian Pacific Railway and Allergan – ended Monday . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.